Physician profile
Brian D Monette
NPI 1699781591
$3,894.06
in general payments reported to CMS, 2019-2025
16 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $385 · 2021: $670 · 2022: $611 · 2023: $623 · 2024: $520 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $564.12 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $484.62 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $483.75 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Abbvie INC. | $466.97 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $382.65 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $326.71 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $320.37 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $308.10 | 2019-2025 | Invega Sustenna, Spravato |
| Allergan, INC. | $265.52 | 2019-2020 | |
| Axsome Therapeutics, INC. | $92.48 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $74.66 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $41.85 | 2019-2023 | Rexulti |
| Indivior INC. | $33.65 | 2024 | Perseris, Sublocade |
| Eisai INC. | $22.44 | 2021 | |
| Noven Pharmaceuticals, INC. | $14.13 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Monette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.